#Switzerland #Zurich #AP-101 #AL-S Pharma #Angela Genge

AL-S Pharma Welcomes Dr. Angela Genge as Chief Medical Officer

In a significant move for ALS research, AL-S Pharma has appointed Professor Dr. Angela Genge as its new Chief Medical Officer. Dr. Genge will oversee the development of AP-101, a potential first-in-class therapy for amyotrophic lateral sclerosis (ALS).

A Prominent Figure in Neurology

Dr. Angela Genge, MD, is a well-respected neurologist affiliated with McGill University in Montreal. She has a commendable background in ALS clinical research and has contributed greatly to the field. Currently the Head of the ALS Global Centre of Excellence for Research and Patient Care at McGill, Dr. Genge is known for her leading role in pivotal clinical trials aimed at combating ALS.

Since 2016, she has also taken on the role of global principal investigator for the clinical trials of AP-101, an investigational antibody designed to target misfolded SOD1, a key factor in the progression of ALS. Her involvement comes at a crucial time, following the recent announcement from AL-S Pharma regarding promising results from the Phase 2 clinical trials of AP-101.

Moving Forward with AP-101

In light of the recent positive topline results from the Phase 2 study of AP-101, Dr. Genge’s expertise will be invaluable to the company's leadership team as they work to advance the development of this innovative therapy. Michael Salzmann, CEO of AL-S Pharma, expressed enthusiasm for Dr. Genge's expanded role, highlighting her extensive experience and recognized leadership in the field.

Expertise and Contributions

Dr. Genge has not only participated in various ALS trials but has also served as an advisor to regulatory bodies, participating in over 80 global clinical advisory boards. Her contributions to ALS research have been acknowledged through various prestigious awards, including the Forbes Norris Award and the PACTALS Excellent Research Award.

In her statement, Dr. Genge shared her excitement about joining AL-S Pharma during this transformative period. She praised the company's commitment to developing AP-101, emphasizing its importance in targeting misfolded SOD1, a major driver of disease progression.

About AP-101

AP-101 is an investigational human antibody identified through Neurimmune's Reverse Translational MedicineTM technology. Aimed specifically at misfolded SOD1, it is being designed to impede the spread of ALS pathology throughout the nervous system. The recent Phase 2 study explored its safety, tolerability, pharmacodynamic markers, and pharmacokinetics across various patient profiles, including those with sporadic ALS and mutant SOD1-ALS.

The importance of this therapy cannot be overstated, as AP-101 has received orphan drug designations from multiple health authorities, underscoring its potential significance in treating those affected by ALS.

AL-S Pharma’s Commitment

Founded in 2016 as a collaborative venture between Neurimmune and TVM Capital Life Science, AL-S Pharma aims to revolutionize ALS treatment through innovations like AP-101. The company is dedicated to a strategic clinical plan developed alongside an international consortium of ALS experts, ensuring comprehensive support for its groundbreaking therapies.

With Dr. Angela Genge at the helm of its medical strategy, AL-S Pharma is poised to make strides in ALS treatment options, providing hope to patients and families affected by this debilitating disease.

For additional details on AP-101, you can visit ClinicalTrials.gov (study number NCT05039099). Stay connected with AL-S Pharma through their LinkedIn page for future updates on their research and therapeutic advancements.